GVK BIO, a global contract research and development organization (CRDO), and BE Pharmaceuticals, a pharmaceutical company that develops, manufactures and markets complex and critical injectable products, have formed a strategic collaboration in drug product development.
 
As part of the partnership, GVK BIO will develop certain set of injectable products for BE Inc. Development work will include pre-formulation studies, formulation development, analytical method development and technology transfer to a BE facility. The goal of the collaboration will be the successful regulatory submissions and marketing authorizations for the products in the U.S., Europe and RoW markets.
 
“GVK BIO’s formulations development team has the technical expertise and track record to deliver on projects, and we look forward to working with the BE team to accelerate product development timelines and reduce cost to market,” said Manni Kantipudi, director and chief executive officer, GVK BIO.
 
Narender Mantena, chief executive officer, speciality generic injectable, BE Pharmaceuticals, said, “We are excited to work with GVK BIO, an established CRDO. This collaboration will support BE in building a robust pipeline, especially for critical injectable products.”